OM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Outset Medical Inc (OM) is not a strong buy at the moment for a beginner investor with a long-term horizon. The stock is currently trading in a bearish technical setup with weak financial performance, declining revenue, and negative earnings trends. Although analysts maintain 'Buy' ratings with reduced price targets and the company projects modest growth in 2026, the lack of significant positive catalysts and mixed sentiment make this stock a hold for now.
The technical indicators suggest a bearish trend. The MACD is negative and contracting, RSI is neutral at 47.989, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 3.709, with key support at 3.182 and resistance at 4.236.
Analysts maintain 'Buy' ratings despite reduced price targets.
Gross margin improved by 16.15% YoY in Q4
Management projects 2026 revenue growth and improved gross margins.
Revenue declined by 2% YoY in Q4 2025, and net income dropped by 23.98% YoY.
EPS declined significantly by 85.32% YoY.
Mixed sentiment due to execution delays and missed guidance in
No significant trading trends from hedge funds or insiders.
In Q4 2025, revenue declined by 2.01% YoY to $28.87 million. Net income dropped by 23.98% YoY to -$19.49 million. EPS fell by 85.32% YoY to -1.07. However, gross margin improved by 16.15% YoY to 42.36%. The company ended 2025 with $173 million in cash reserves and reduced its adjusted net loss from $19.3 million to $15.1 million.
Analysts from BTIG and TD Cowen maintain 'Buy' ratings with reduced price targets of $15 and $12, respectively. RBC Capital maintains a 'Sector Perform' rating with a reduced price target of $7, citing mixed sentiment due to execution delays and missed guidance in 2025.
